The role of insulin, glucagon, dexamethasone, and leptin in the regulation of ketogenesis and glycogen storage in primary cultures of porcine hepatocytes prepared from 60 kg pigs.
A study was conducted to elucidate hormonal control of ketogenesis and glycogen deposition in primary cultures of porcine hepatocytes. Hepatocytes were isolated from pigs (54-68 kg) by collagenase perfusion and seeded into collagen-coated T-25 flasks. Monolayers were established in medium containing fetal bovine serum for 1 day and switched to a serum-free medium for the remainder of the culture period. Hepatocytes were maintained in DMEM/M199 containing 1% DMSO, dexamethasone (10(-6) or 10(-7) M), linoleic acid (3.4 x 10(-5) M), and carnitine (10(-3) M) for 3 days. On the first day of serum-free culture, insulin was added at 1 or 100 ng/ml and glucagon was added at 0, 1, or 100 ng/ml. Recombinant human leptin (200 ng/ml) was added during the final 24 h; medium and all cells were harvested on the third day. Concentrations of acetoacetate and beta-hydroxybutyrate (ketone bodies) in media and glycogen deposition in the cellular compartment were determined. Ketogenesis was highly stimulated by glucagon (1 and 100 ng/ml) and inhibited by insulin. In contrast, glycogen deposition was stimulated by insulin and attenuated by glucagon; high insulin was also associated with a reduction in the ketone body ratio (acetoacetate:beta-hydroxybutyrate). High levels of dexamethasone stimulated ketogenesis, but inhibited glycogen deposition at low insulin. Culture of cells with leptin for 24 h, over the range of insulin, glucagon, and dexamethasone concentrations had no effect on either glycogen deposition or ketogenesis. These data suggest that while adult porcine hepatocytes are indeed sensitive to hormonal manipulation, leptin has no direct influence on hepatic energy metabolism in swine.
Fernández-Fígares
I
I
Growth Biology Laboratory, Animal and Natural Resources Institute, Beltsville Agricultural Research Center-East, USDA/ARS, Building 200, Room no. 202, USDA, MD 20705, USA.
Shannon
A E
AE
Wray-Cahen
D
D
Caperna
T J
TJ
D000818:Animals; D001835:Body Weight; D002331:Carnitine / Q000008:administration & dosage; D002478:Cells, Cultured; D016895:Culture Media, Serum-Free; D003907:Dexamethasone / Q000008:administration & dosage; D005934:Glucagon / Q000008:administration & dosage / Q000502:physiology*; D005938:Glucocorticoids / Q000008:administration & dosage / Q000502:physiology; D006003:Glycogen / Q000378:metabolism*; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000502:physiology*; D007657:Ketone Bodies / Q000096:biosynthesis*; D020738:Leptin / Q000008:administration & dosage / Q000502:physiology; D019787:Linoleic Acid / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D013552:Swine
D016895:Culture Media, Serum-Free; D005938:Glucocorticoids; D007328:Insulin; D007657:Ketone Bodies; D020738:Leptin; D011994:Recombinant Proteins; D003907:Dexamethasone; D006003:Glycogen; D005934:Glucagon; D019787:Linoleic Acid; D002331:Carnitine